Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
1
pubmed:dateCreated
2008-11-3
pubmed:abstractText
Retinal neovascularization (NV) occurs in various ocular disorders including proliferative diabetic retinopathy, retinopathy of prematurity and secondary neovascular glaucoma, which often result in blindness. Vascular endothelial growth factor (VEGF) is an essential growth factor for angiogenesis, and is particularly regulated by hypoxia inducible factor-1alpha (HIF-1alpha) under hypoxic conditions. Therefore, HIF-1alpha and VEGF could provide targets for therapeutic intervention on retinal NV. In this study, we investigated the inhibitory effects of small interfering RNA (siRNA) targeting HIF-1alpha and VEGF on the expression of HIF-1alpha and VEGF in human umbilical vein endothelial cells (HUVEC) in vitro and on retinal NV in vivo. siRNA-expressing plasmids targeting human HIF-1alpha (HIF-1alpha siRNA) and human VEGF(165) (VEGF siRNA) were constructed. They were transfected and co-transfected to HUVEC and C57BL/6J mice of ischemic retinopathy model. HIF-1alpha siRNA and VEGF siRNA specifically downregulated HIF-1alpha and VEGF at both mRNA and protein levels in vitro and in vivo. Neovascular tufts and neovascular nuclei were decreased in gene therapy group compared to control hypoxia group. Co-transfection of HIF-1alpha siRNA and VEGF siRNA resulted in maximal effects on VEGF suppression in vitro and in vivo. It also manifested the maximal inhibitory effect on retinal NV. These results indicate that the application of HIF-1alpha siRNA and VEGF siRNA technology holds great potential as a novel therapeutic for retinal NV.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jan
pubmed:issn
1097-4652
pubmed:author
pubmed:copyrightInfo
(c) 2008 Wiley-Liss, Inc.
pubmed:issnType
Electronic
pubmed:volume
218
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
66-74
pubmed:meshHeading
pubmed-meshheading:18767037-Animals, pubmed-meshheading:18767037-Base Sequence, pubmed-meshheading:18767037-Blotting, Western, pubmed-meshheading:18767037-Cells, Cultured, pubmed-meshheading:18767037-Disease Models, Animal, pubmed-meshheading:18767037-Down-Regulation, pubmed-meshheading:18767037-Gene Therapy, pubmed-meshheading:18767037-Humans, pubmed-meshheading:18767037-Hypoxia-Inducible Factor 1, alpha Subunit, pubmed-meshheading:18767037-Immunohistochemistry, pubmed-meshheading:18767037-Mice, pubmed-meshheading:18767037-Mice, Inbred C57BL, pubmed-meshheading:18767037-RNA, Messenger, pubmed-meshheading:18767037-RNA, Small Interfering, pubmed-meshheading:18767037-Retinal Neovascularization, pubmed-meshheading:18767037-Reverse Transcriptase Polymerase Chain Reaction, pubmed-meshheading:18767037-Transfection, pubmed-meshheading:18767037-Vascular Endothelial Growth Factor A
pubmed:year
2009
pubmed:articleTitle
Inhibition of retinal neovascularization by gene transfer of small interfering RNA targeting HIF-1alpha and VEGF.
pubmed:affiliation
Department of Ophthalmology, Xiangya Hospital, Central South University, Changsha, Hunan, China.
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't